Ataxia Diagnosis and Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: February 15, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 30.0 billion |
|
Revenue Forecast in 2030 |
US$ 64.62 billion |
|
CAGR |
8.9% |
|
Base Year of Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Type, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global ataxia diagnosis and treatment market was valued at US$ 30.0 billion in 2021 and is expected to register a revenue CAGR of 8.9% to reach US$ 64.62 billion in 2030.
Ataxia Diagnosis and Treatment Market Fundamentals
Ataxia is the absence of voluntary coordination of muscle movements, which can cause irregularities in speech, walking, and eye movement. It is a clinical sign of malfunction in the cerebellum and other areas of the neurological system that control movement. These neural system disorders manifest in a variety of ways, with various outcomes and potential causes. Hemiataxia is the medical term for ataxia that only affects one side of the body.
Deficits in thiamine, vitamin B-12, and vitamin E can also result from increasing alcohol and drug usage. Ataxia is thought to be primarily caused by an inadequate supply of critical nutrients in the body, which is expected to fuel market revenue growth over the forecast period.
Ataxia can be brought on by harming other areas of the nervous system. However, it typically occurs due to damage to the cerebellum, a region of the brain. This harm may be the result of underlying disorders, such as MS, a head injury, a shortage of oxygen to the brain, or prolonged, severe alcohol usage.
Ataxias can be roughly divided into those that are acquired/degenerative and those that are genetic (with or without a family history). A family history of ataxia is implied by the term sporadic. Ataxias that have been acquired can be immune-mediated, degenerative, the result of deficient conditions, toxic, or related to infections (HIV, sporadic Creutzfeldt-Jakob disease, and progressive multifocal leukoencephalopathy). Ataxias that are inherited might be X-linked, autosomal dominant, autosomal recessive, or mitochondrial (maternal) in nature. Even though they are inherited, metabolic illnesses (such as Niemann-Pick type C and Tay-Sachs disease) can appear as late-onset ataxia without a family history, highlighting the necessity for rigorous clinical scrutiny and thorough and appropriate laboratory testing. Hereditary ataxia patients typically have shorter life expectancies than the average population, while some do survive well up to their 50s, 60s, or beyond. The prognosis for acquired ataxia relies on the underlying reason. While certain conditions may get better or stay the same, others may deteriorate with time and shorten life expectancy.The cause of ataxia determines the treatment. Adaptive tools, such as walkers or canes, could keep one independent. Regular aerobic exercise, speech treatment, occupational therapy, and physical therapy can all be beneficial. Physical treatment to improve the patient’s mobility and aid in coordination, helping with activities of daily living, such as feeding, through occupational therapy. Speech therapy is utilized to facilitate swallowing and enhance speech.
[54654675]
Ataxia Diagnosis and Treatment Market Dynamics
Ataxia’s rising prevalence and incidence are anticipated to fuel the market’s expansion. Ataxia disease has received widespread recognition as a serious clinical issue with a significant burden of morbidity and mortality. Therefore, the global ataxia diagnosis and treatment market may be driven by rising incidence and incident rates of ataxia affecting various age groups. This, in turn, will play a significant role in determining market revenue growth.
The market revenue growth rate is also expected to be boosted by increased spending on the development of advanced healthcare infrastructure by both public and private entities across developed and developing countries. The deployment of sophisticated healthcare technology is the subject of ongoing research and development, which is likely to expand the market’s potential for expansion.
The global ataxia diagnosis and treatment market is experiencing revenue growth challenges due to the rigorous regulatory environment for ataxia medication approval. The high cost of treating ataxia, combined with a lack of skilled medical personnel, is a significant barrier to the global market. The absence of a single approved drug for the treatment of ataxia also hinders the revenue growth of the global market for ataxia treatment.
Ataxia Diagnosis and Treatment Market Ecosystem
The global ataxia diagnosis and treatment market has been analyzed from three perspectives: type, indication, and region.
Ataxia Diagnosis and Treatment Market by Type
Based on type, the global ataxia diagnosis and treatment market has been segmented into diagnosis and treatment.
The diagnosis segment is further sub-segmented into brain scans, genetic testing, lumbar puncture, and others. The brain scans segment is predicted to acquire the largest revenue share of the global ataxia diagnosis and treatment market. This is the result of the great efficacy of this diagnosis method in identifying the underlying cause of an illness and validating the most suitable course of treatment. Additionally, the complexity of alternative diagnoses, such as gene testing, in comparison to brain scans, is expected to help this market sector grow in the future.
The treatment segment is further sub-segmented into medications, such as levodopa, pramipexole, venlafaxine, and others. The levodopa sub-segment accounts for a significant revenue share in the treatment segment for ataxia. It has been shown to reduce Parkinsonian-like symptoms in ataxic patients, such as reduced gait or limb ataxia, slow saccades, or decreased tendon reflexes. It is used to treat various forms of ataxia, such as spinocerebellar ataxia and episodic ataxia.
Ataxia Diagnosis and Treatment Market by Indication
[5675645]
Based on indication, the global ataxia diagnosis and treatment market has been segmented into Friedreich’s ataxia, episodic ataxia, ataxia-telangiectasia, spinocerebellar ataxias, and others.
The Friedrich’s ataxia segment dominates the global ataxia diagnosis and treatment market. This is due to the prevalence of this type of ataxia in individuals between the ages of 10 and 15, as well as growing advancements in therapy that put an emphasis on reducing symptoms while maintaining comfort and function.
Ataxia Diagnosis and Treatment Market by Region
Based on region, the global ataxia diagnosis and treatment market has been segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America is expected to account for the largest revenue share in the global ataxia diagnosis and treatment market. This can be ascribed to rising Ataxia prevalence, increasing government funding for research initiatives, and growing number of support groups for patient diagnosis and care. The U.S. National Library of Medicine estimates that ataxia affects 1 in 40,000 to 1,000,000 people worldwide. In the United States, around 150,000 people are reported to be suffering from this illness. This necessitates an increase in ataxia diagnosis and treatment in the country. Furthermore, given the prominence of key competitors in the industry, the region’s market expansion is expected to be strengthened in the next few years.
The market in Asia Pacific is projected to register growth at the highest revenue CAGR during the forecast period due to an increase in the patient population with inherited strains of ataxia, higher awareness of ataxia, and government initiatives to treat these diseases.
Ataxia Diagnosis and Treatment Market Competitive Landscape
The prominent players operating in the global ataxia diagnosis and treatment market are:
Ataxia Diagnosis and Treatment Market Strategic Developments
The global ataxia diagnosis and treatment market is expected to register growth at a revenue CAGR of 8.9% in the forecast period.
CRISPR Therapeutics AG, Bio-Techne Corporation, Cellectis SA, Eli Lilly & Company, and GlaxoSmithKline Plc are among the key players in the global ataxia diagnosis and treatment market.
Increasing prevalence of ataxia and growing number of incidences of autoimmune diseases are fueling revenue growth in the global market.
Asia Pacific is expected to register the highest revenue growth in the global ataxia diagnosis and treatment market in the forecast period.
The global ataxia diagnosis and treatment market was valued at US$ 30 billion in 2021.
*Insights on financial performance are subject to the availability of information in the public domain